Hepalink Strengthens Biologics Presence With OncoVent JV
This article was originally published in PharmAsia News
Executive Summary
China's Shenzhen Hepalink, a public company that claims to be one of the largest makers of heparin in the world, is aiming to build up its R&D activities for biologics through a newly formed Chinese JV with OncoQuest, which will leverage the two companies’ expertise and assets to develop novel cancer immunotherapies.
You may also be interested in...
Deal Watch: Japan’s JCR Inks Pacts With Sumitomo Dainippon, Alexion
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.